NCT03037164Phase 3Active not recruiting

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-07-31Estimated

Enrollment · participants692Actual

Source updated2026-03-20Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-11-10 · 4 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~800 participants (planned)~~

+ After

692 participants (actual)

Primary completion date changed

− Before

~~31 Oct 2025~~

+ After

31 Jul 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Anemia

Treatments or interventions studied

Not recorded

Primary outcomes · main study measures

Read the study measures

measure: Adjusted hemoglobin increment; description: The difference between the pre-transfusion and post transfusion episode hemoglobin values divided by the total hemoglobin content transfused, averaged over one or more transfusion episodes in patients without active bleeding at baseline (active bleeding is defined as WHO Grade 3 or 4 bleeding); timeFrame: 15 minutes - 24 hours post transfusion; measure: Adverse Events; description: Proportion of patients with any treatment-emergent adverse events (AEs) possibly, probably, or definitely related to study RBC transfusion through 28 days after the last study transfusion.; timeFrame: 28 days; measure: Treatment emergent antibodies; description: The proportion of patients with treatment emergent antibodies with confirmed specificity to IBS RBCs; timeFrame: 75 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history